You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
A study of both tissue and blood samples from patients in a small trial found that liquid biopsy may detect putative resistance mutations missed in tissue.
The company has overcome one major hurdle and is poised to clear another in the first half of this year, clearing the way for new test development.
The firm said its revenues for the three months ended Dec. 31, 2019 were $62.9 million compared to $32.9 million in the same quarter of 2018.
Paired tumor/germline analysis is not routinely done in cancer care, but some labs are starting to report incidental germline findings alongside patient's tumor profiles.
Medicare Administrative Contractor Palmetto released its final local coverage decision last year, and WPSIC has now aligned its coverage.
Clinical sequencing consumables revenues grew 20 percent year over year and accounted for just over 40 percent of total consumables shipments in 2019.
The findings should spur cancer centers to review testing rates and address barriers, said experts from Hackensack University, Cota Healthcare, and Guardant Health.
On Monday Qiagen reiterated its preliminary 2019 earnings figures and addressed an investor's wrath, while Guardant Health highlighted its cancer testing plans.
The company plans to submit a companion diagnostic version of its sequencing-based liquid biopsy test Guardant360 to various regulatory bodies.
A federal court said Guardant CEO Helmy Eltoukhy deleted emails pertaining to two similar cases, but it remains unclear whether he did so intentionally.
The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.
Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.
A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.
In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.